Takeda Pharmaceutical said on January 30 that it has filed a new Japanese drug application for the antibody drug conjugate (ADC) mirvetuximab soravtansine, targeting folate receptor alpha (FRα)-positive, platinum-resistant recurrent ovarian cancer (PROC). The drug has been designated as an…
To read the full story
Related Article
- Japan Panel to Weigh Keytruda SC, J&J Psoriasis Pill among 6 NMEs on Aug. 24
August 18, 2026
- Takeda Snags Japan Rights to ImmunoGen’s ADC
August 30, 2023
BUSINESS
- Eisai Maps Out Next-Gen Alzheimer’s Strategy beyond Leqembi
August 18, 2026
- Enhertu Hits PIII Primary Goal in 1st-Line HER2-Mutant NSCLC
August 18, 2026
- Enhertu Combo Scores China Nod in 1st-Line HER2 Breast Cancer
August 18, 2026
- Santen Releases Glaucoma Drug Rhopressa in Japan
August 18, 2026
- Yaz AGs Now Available in Japan, Hisamitsu Handling Distribution
August 18, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





